- By Mariko Oi
- Enterprise reporter
1 hour in the past
The maker of the weight-loss drug, Wegovy, has change into Europe’s most useful firm, dethroning French luxurious group LVMH.
Shares rose after Danish pharmaceutical big Novo Nordisk launched the favored drug within the UK.
At Monday’s shut, the corporate had a market valuation of $428 billion (£339 billion).
Wegovy is an weight problems remedy that’s taken as soon as every week and methods folks into considering they’re already full, in order that they find yourself consuming much less and dropping pounds.
Wegovy and Ozempic – a diabetes drug with comparable results – have been described as “miracle cures”.
However consultants warn that the vaccinations are neither a fast repair nor a substitute for a nutritious diet and train.
In research, customers typically regained weight after stopping remedy.
There was a world scarcity of vaccinations, so solely restricted portions had been delivered to the British Nationwide Well being System (NHS).
The corporate stated it could proceed to limit international provides as it really works to ramp up manufacturing.
Within the UK, NHS tips say sufferers can solely entry Wegovy, which incorporates the drug semaglutide, if they’re considerably obese and have weight-related well being issues.
In keeping with the Group for Financial Co-operation and Growth (OECD), virtually one in three adults within the UK are overweight, the best in Europe.
Though the outcomes have but to be totally verified, consultants agreed that the outcomes are doubtlessly important.
